DK200000375U1 - Polypeptidsammensætninger med forbedret stabilitet. - Google Patents

Polypeptidsammensætninger med forbedret stabilitet.

Info

Publication number
DK200000375U1
DK200000375U1 DK200000375U DKBA200000375U DK200000375U1 DK 200000375 U1 DK200000375 U1 DK 200000375U1 DK 200000375 U DK200000375 U DK 200000375U DK BA200000375 U DKBA200000375 U DK BA200000375U DK 200000375 U1 DK200000375 U1 DK 200000375U1
Authority
DK
Denmark
Prior art keywords
glycerin
compositions
polypeptide
chemical stability
improved stability
Prior art date
Application number
DK200000375U
Other languages
Danish (da)
English (en)
Inventor
Michael Rosario Defelippis
Michael Allen Dobbins
Alby David Sharknas
Alex Mark Prokai
Vincent Rinella Junior Joseph
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27341882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK200000375(U1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from JP37720899A external-priority patent/JP2001181203A/ja
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK200000375U1 publication Critical patent/DK200000375U1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK200000375U 1999-12-16 2000-12-14 Polypeptidsammensætninger med forbedret stabilitet. DK200000375U1 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17113599P 1999-12-16 1999-12-16
JP37720899A JP2001181203A (ja) 1999-12-16 1999-12-28 安定性が改良されたポリペプチド組成物
US18103000P 2000-02-08 2000-02-08

Publications (1)

Publication Number Publication Date
DK200000375U1 true DK200000375U1 (da) 2001-03-16

Family

ID=27341882

Family Applications (1)

Application Number Title Priority Date Filing Date
DK200000375U DK200000375U1 (da) 1999-12-16 2000-12-14 Polypeptidsammensætninger med forbedret stabilitet.

Country Status (15)

Country Link
EP (1) EP1242121B1 (de)
JP (1) JP2003523972A (de)
CN (1) CN1409640A (de)
AT (1) ATE288765T1 (de)
AU (1) AU777570B2 (de)
BR (1) BR0016334A (de)
CA (1) CA2394213A1 (de)
DE (2) DE60018105T2 (de)
DK (1) DK200000375U1 (de)
EA (1) EA004631B1 (de)
ES (1) ES2236010T3 (de)
IL (1) IL150129A0 (de)
PL (1) PL355378A1 (de)
PT (1) PT1242121E (de)
WO (1) WO2001043762A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5562510B2 (ja) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス 修飾ｇｌｐ−１の安定な処方剤
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
US20040121009A1 (en) * 2002-10-17 2004-06-24 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US20050267222A1 (en) * 2002-10-22 2005-12-01 Dainippon Pharmaceutical Co. Ltd. Stabilized composition
EP1633391B1 (de) 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilisierte pharmazeutische peptid zusammensetzungen
ATE541582T1 (de) 2003-06-03 2012-02-15 Novo Nordisk As Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
KR101009858B1 (ko) 2003-11-20 2011-01-19 솔베이(소시에떼아노님) 유기 화합물의 제조 방법
KR101243648B1 (ko) 2003-11-20 2013-03-14 노보 노르디스크 에이/에스 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제
EP1789434B1 (de) 2004-08-31 2013-11-20 Novo Nordisk A/S Verwendung von tris(hydroxymethyl)-aminomethan zur stabilisierung von peptiden, polypeptiden und proteinen
CA2586771A1 (en) 2004-11-12 2006-05-18 Novo Nordisk A/S Stable formulations of insulinotropic peptides
ES2346005T3 (es) * 2006-07-27 2010-10-07 Cognis Ip Management Gmbh Procedimiento para la obtencion de glicerina.
TWI478875B (zh) 2008-01-31 2015-04-01 Solvay 使水性組成物中之有機物質降解之方法
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
FR2935968B1 (fr) 2008-09-12 2010-09-10 Solvay Procede pour la purification de chlorure d'hydrogene
MX344293B (es) 2008-10-17 2016-12-13 Sanofi Aventis Deutschland Combinacion de una insulina y un agonista de glp-1.
PT2498802E (pt) 2009-11-13 2015-04-13 Sanofi Aventis Deutschland Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
BR112012011403B8 (pt) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland composição farmacêutica líquida compreendendo um agonista glp-1 e metionina e uso da mesma
JP2011195557A (ja) * 2010-02-24 2011-10-06 Kyorin Pharmaceutical Co Ltd 糖アルコールの選択方法
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
SI2433651T1 (sl) 2010-09-03 2013-06-28 Aug. Hedinger Gmbh & Co. Kg Postopek ugotavljanja aldehidov in ketonov v glicerinu
CN107759771A (zh) 2010-09-30 2018-03-06 索尔维公司 天然来源的环氧氯丙烷的衍生物
US9097692B2 (en) 2010-10-01 2015-08-04 Aug. Hedinger Gmbh & Co. Kg Method for quantitatively determining impurities in glycerin
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
MX2014012096A (es) 2012-04-11 2014-11-21 Novo Nordisk As Formulaciones de insulina.
LT3229828T (lt) 2014-12-12 2023-06-12 Sanofi-Aventis Deutschland Gmbh Insulino glargino/liksisenatido fiksuoto santykio kompozicija
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AU2017378102B2 (en) 2016-12-16 2022-10-13 Novo Nordisk A/S Insulin containing pharmaceutical compositions
CN111050750A (zh) 2017-08-24 2020-04-21 诺沃挪第克公司 Glp-1组合物及其用途
JP2023505190A (ja) * 2019-12-06 2023-02-08 ドクター メアリー モリス アンド アソシエイツ リミテッド ライアビリティ カンパニー １型糖尿病の治療および予防のための方法および組成物
MX2022009523A (es) 2020-02-18 2022-09-09 Novo Nordisk As Formulaciones farmaceuticas.
CN116847869A (zh) * 2020-10-08 2023-10-03 美商玛丽莫里斯博士联合有限责任公司 用于治疗和预防1型糖尿病的方法和组合物
WO2024081659A1 (en) * 2022-10-13 2024-04-18 Archer Daniels Midland Company Purification of glycerin as excipient in parenteral pharmaceutical applications

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189964B1 (pl) * 1996-06-20 2005-10-31 Novo Nordisk As Wodny preparat insuliny, środek farmaceutyczny dopodawania pozajelitowego oraz sposób poprawiania chemicznej stabilności preparatów insuliny

Also Published As

Publication number Publication date
EP1242121B1 (de) 2005-02-09
WO2001043762A3 (en) 2002-01-10
CN1409640A (zh) 2003-04-09
WO2001043762A2 (en) 2001-06-21
AU777570B2 (en) 2004-10-21
AU2049301A (en) 2001-06-25
ES2236010T3 (es) 2005-07-16
EA004631B1 (ru) 2004-06-24
EA200200684A1 (ru) 2003-02-27
PT1242121E (pt) 2005-05-31
IL150129A0 (en) 2002-12-01
JP2003523972A (ja) 2003-08-12
DE20021079U1 (de) 2001-03-22
PL355378A1 (en) 2004-04-19
CA2394213A1 (en) 2001-06-21
EP1242121A2 (de) 2002-09-25
BR0016334A (pt) 2002-09-10
DE60018105D1 (de) 2005-03-17
ATE288765T1 (de) 2005-02-15
DE60018105T2 (de) 2005-12-29

Similar Documents

Publication Publication Date Title
DK200000375U1 (da) Polypeptidsammensætninger med forbedret stabilitet.
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
SE0002102D0 (sv) Chemical compound
TR200402703T4 (tr) Çözünür CTLA4 mutantları ve bunların kullanımı.
TR200201874T2 (tr) Proteaz inhibitörleri olarak yeni bileşikler ve bileşimler.
PT1109812E (pt) Pirrolobenzodiazepinas
BRPI0414539A (pt) composto, composição farmacêutica, e, uso de um composto
ATE380822T1 (de) Funf-helix protein
MY133969A (en) Indoloquinazolinones
TR199802079T2 (xx) D-Manitol ve haz�rlanmas�.
BR0009421A (pt) Inibidores de ligação lfa-1 aos icams e uso dos mesmos
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
TR200501541T2 (tr) Leu-hirudinin e.coli ile kültür ortamında ayrışarak üretilmesinin sinyal sekansları
DE60001850T2 (de) Chalcon coumarine
TR200101493T2 (tr) Eletriptan hidrobromid monohidrat
TR200102742T2 (tr) Rezorsinol türevleri
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
TR200401875T2 (tr) Endoparazit öldürücü bileşimler
BR0207033A (pt) variantes de amina oxidase ap1
EA200400393A1 (ru) Антитела против каспазы-8, их получение и применение
TR200102815T1 (tr) Displazili dokunun tespiti için kullanılacak in vivo lekeleme bileşik ve metodları.
WO2001070384A3 (de) Verwendung von duftalkoholalkoxylaten als solubilisierhilfsmittel
IT1319871B1 (it) Uso degli ultrasuoni al fine di migliorare la conservazione del lattenello stabilimento di produzione.
ITFO20000026V0 (it) Uso degli ultrasuoni al fine di migliorare la conservazione del lattenello stabilimento di produzione.

Legal Events

Date Code Title Description
URF Utility model: application refused